- This year introduces the DACH Bioprocessing Excellence Awards, recognising manufacturing innovation, operational excellence, and leadership across cell & gene therapy, biologics, and oligos & peptides.
- The programme brings cell & gene therapy, biologics, and oligos & peptides together in one agenda, reflecting the shift toward multi-platform and hybrid manufacturing models.
- There is a stronger emphasis on late-stage CMC, tech transfer, GMP readiness, and cost-of-goods, aligning discussions with real-world commercialisation challenges.
- New sessions highlight digital and automated manufacturing, including digital twins, PAT, real-time release testing, and closed-system operations.
- The agenda places greater focus on patient-centric and decentralized CGT models, covering autologous manufacturing, point-of-care production, and chain of identity.
- Discussions are tailored to DACH-specific operational and sustainability priorities, including facility design, supplier risk, energy efficiency, and regional regulatory expectations.
Senior Attendees
Connect with manufacturing leaders, site heads, engineering directors and technical decision-makers from Ireland, the UK and Europe's leading biologics and advanced therapies organisations.
Expert Speakers
Learn from industry pioneers sharing insights on biologics manufacturing, antibody engineering, ADCs, oligonucleotides, peptides, facility expansion, process innovation and operational excellence.
Companies Represented
Engage with biopharma companies, CDMOs, technology providers, solution partners supporting the growth of Europe's advanced therapeutics ecosystem.
Networking Hours
Build relationships with peers, partners and potential customers through dedicated networking sessions, roundtables and discussions designed to foster collaboration across the industry.
